Chief Executive Officer
Colin Denver is an experienced sales professional with over 12 years working in the Life Science and Diagnostic fields. He has experience in establishing new organisations having set up Bioline in Australia in 2004. Colin enjoyed continued growth while at Bioline with quarter on quarter growth achieved since inception. Colin went on to manage sales in Asia/Pacific for Meridian Bioscience (post Bioline acquisition) and drove consistent growth within the territory. Colin started as Vice President of Sales and Marketing for SpeeDx, responsible for the promotion of all SpeeDx branded products as well as acquisition of new licensing and commercial agreements. He now holds the role of CEO, overseeing the expansion of SpeeDx as products are launched across Europe, United States and Australia/New Zealand. Colin holds a Bachelor of Science from Pepperdine University and a Post Graduate Diploma of Management from MGSM.
ALISON TODD PhD
Chief Scientific Officer
Dr Alison Todd has extensive experience within the pharmaceutical industry where she developed several novel molecular analytical technologies which have been used for basic research, preclinical/clinical drug development and in vitro diagnostics. Her specific areas of scientific expertise include nucleic acid chemistry, particularly target amplification and catalytic DNA technologies, and the biology of cancer and viral diseases. Prior to founding SpeeDx, Alison was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. She was awarded the highly prestigious Johnson & Johnson Philip B. Hofmann Research Scientist Award which is a worldwide award for outstanding achievement in the field of research and development. Alison is an inventor on 18 patents/patent applications and her techniques have been used for molecular monitoring in nine international clinical trials for patients with HIV, leukaemia and various solid tumours. She has successfully championed multiple inventions through to product commercialization in various fields. Alison studied at the University of Sydney, obtaining a BSc (Hons 1st Class), and graduating as Dux of the Physiology Department. Later she completed a PhD within the Faculty of Medicine at the same university. Alison maintains an active involvement within the academic community and holds an adjunct appointment as Senior Visiting Fellow at the University of New South Wales.
ELISA MOKANY PhD
Chief Technology Officer
Elisa Mokany is a co-founder and the Chief Technology Officer at SpeeDx. In this role she leads the development of innovative diagnostic technologies and commercialization of infectious disease and antibiotic resistance tests. Elisa has 17 years’ experience in medical research, she has worked for St Vincent’s hospital developing tests for the diagnosis of colorectal cancer and later at Johnson & Johnson Research (JJR) where she developed diagnostic tests for leukemia and was involved in the commercialisation of proprietary technology known as DzyNA PCR. While at JJR, Elisa undertook studies towards her PhD, which involved co-invention of the novel nucleic acid technology, PlexZymes . Elisa is an inventor on 8 patents/patent applications involving nucleic acid analysis including the novel PlexPrime technology which has multiple applications in the in vitro diagnostic field. Elisa studied at the University of NSW, obtaining a BSc (Hons 1st Class) and later completed her PhD at JJR in conjunction with the School of Biotechnology and Biomolecular Science at the University of New South Wales.
Chief Financial Officer
Bhavin Raval has nearly 30 years of financial leadership experience across a broad range of industries including the last 16 years with Life Science and Biotech companies. He brings financial and executive leadership experience to SpeeDx in the areas of business operations, fiscal management and strategy, commercial partnering, M&A and integration activities, and private equity fundraising. His previous employers include Johnson & Johnson Research Pty Limited, Victor Chang Cardiac Research Institute and Calimmune Inc. He was a part of the senior management team of Calimmune Inc. that was acquired by CSL for a value of up to USD 416 M in August 2017. Bhavin is a Fellow Member of CPA Australia as well as a Fellow Member of the Governance Institute of Australia.